Close



Jan 19, 2023 04:05PM
Jan 19, 2023 04:05PM
Jan 19, 2023 04:05PM
Nov 22, 2022 04:04PM
Nov 22, 2022 04:01PM
Nov 14, 2022 05:40AM
Nov 14, 2022 02:12AM Indivior PLC to Acquire Opiant Pharmaceuticals
Nov 14, 2022 02:10AM
Aug 22, 2022 04:10PM
Aug 22, 2022 04:05PM
Aug 12, 2022 07:30AM
Aug 11, 2022 04:05PM
Aug 8, 2022 04:05PM
Aug 2, 2022 04:06PM Opiant Pharmaceuticals (OPNT) Granted US Patent With Claims Covering OPNT003
Aug 2, 2022 04:05PM
Jun 8, 2022 04:07PM
Jun 8, 2022 04:05PM
Jun 8, 2022 04:05PM
Jun 1, 2022 04:07PM
Jun 1, 2022 04:05PM
Jun 1, 2022 04:05PM Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
May 10, 2022 04:01PM
May 10, 2022 04:01PM
Apr 27, 2022 04:04PM
Apr 27, 2022 04:01PM
Apr 27, 2022 04:01PM
Mar 15, 2022 04:05PM
Mar 15, 2022 04:05PM Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Feb 10, 2022 08:09AM
Feb 10, 2022 08:01AM
Feb 10, 2022 08:00AM
Feb 10, 2022 08:00AM
Jan 24, 2022 04:05PM
Jan 24, 2022 04:05PM
Jan 24, 2022 04:05PM Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
Dec 8, 2021 04:06PM
Nov 11, 2021 04:05PM
Nov 11, 2021 04:05PM
Nov 4, 2021 04:08PM
Nov 4, 2021 04:05PM
Nov 4, 2021 04:05PM
Aug 5, 2021 04:01PM Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 5, 2021 04:01PM
Jul 12, 2021 08:00AM
Jul 12, 2021 08:00AM
Jul 6, 2021 04:39PM
Jul 6, 2021 04:01PM
Jul 6, 2021 04:01PM
Mar 31, 2021 04:01PM Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
Mar 31, 2021 04:01PM

251,576 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All